Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation

Area of Science:

• Cell Biology
• Molecular Oncology
• Cancer Therapeutics

Background:

• G(2) checkpoint abrogation is a novel anticancer strategy targeting p53-deficient tumors.
• The drug UCN-01 induces mitotic entry and cell death by abrogating the G(2) cell cycle arrest.
• The precise mechanism of UCN-01-induced cell death, termed "mitotic catastrophe," remains poorly defined.

Purpose of the Study:

• To elucidate the mechanism of cell death induced by G(2) checkpoint abrogation.
• To identify pathways that regulate UCN-01-induced apoptosis.
• To develop an improved anticancer treatment strategy by combining UCN-01 with inhibitors of specific antiapoptotic pathways.

Main Methods:

• Investigated UCN-01 effects on cell cycle progression and cell death.
• Analyzed the role of mitotic spindle checkpoint proteins (Mad2, Bub1, BubR1, Mps1, Aurora B, survivin) in UCN-01 treatment.
• Assessed the involvement of the mitochondria-associated apoptosis pathway.
• Examined the impact of genetic or pharmacologic inhibition of survivin, Aurora B, or CDK1 on UCN-01 efficacy.

Main Results:

• UCN-01 induces a mitotic arrest dependent on the spindle checkpoint proteins.
• Apoptosis-associated pathways are activated during mitotic arrest, with Mad2 playing a proapoptotic role.
• Survivin and Aurora B are required for mitotic arrest but also act anti-apoptotically by inhibiting Bcl-2 and Bax.
• Inhibiting survivin or Aurora B significantly enhances UCN-01-induced apoptosis, demonstrating synergistic effects.

Conclusions:

• UCN-01 treatment leads to mitotic catastrophe via a mechanism involving the spindle checkpoint and apoptosis pathways.
• The survivin/Aurora B pathway restrains UCN-01-induced apoptosis.
• Combining UCN-01 with inhibitors of the survivin/Aurora B pathway represents a promising, selective strategy for p53-deficient cancer treatment.